Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) PT at $14.67

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) have earned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $14.67.

Several equities analysts recently issued reports on the company. Robert W. Baird boosted their price objective on Cogent Biosciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research report on Thursday, September 5th. Wedbush reiterated a “neutral” rating and issued a $11.00 price target (up previously from $10.00) on shares of Cogent Biosciences in a report on Tuesday, September 3rd. JPMorgan Chase & Co. dropped their price objective on shares of Cogent Biosciences from $22.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. HC Wainwright cut their price objective on shares of Cogent Biosciences from $19.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $18.00 target price on shares of Cogent Biosciences in a report on Wednesday, August 7th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its stake in Cogent Biosciences by 234.5% in the first quarter. Russell Investments Group Ltd. now owns 10,014 shares of the technology company’s stock valued at $67,000 after purchasing an additional 7,020 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Cogent Biosciences during the fourth quarter worth $70,000. NEOS Investment Management LLC acquired a new position in Cogent Biosciences during the fourth quarter worth $76,000. Quest Partners LLC bought a new stake in Cogent Biosciences during the second quarter worth $89,000. Finally, 49 Wealth Management LLC lifted its stake in Cogent Biosciences by 20.5% in the first quarter. 49 Wealth Management LLC now owns 13,137 shares of the technology company’s stock valued at $91,000 after acquiring an additional 2,236 shares during the last quarter.

Cogent Biosciences Stock Performance

COGT opened at $10.63 on Wednesday. The firm’s fifty day moving average is $9.62 and its two-hundred day moving average is $8.19. The firm has a market cap of $1.16 billion, a PE ratio of -4.29 and a beta of 1.70. Cogent Biosciences has a twelve month low of $3.67 and a twelve month high of $12.14.

Cogent Biosciences (NASDAQ:COGT) last issued its quarterly earnings data on Tuesday, August 6th. The technology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period last year, the business earned ($0.59) earnings per share. Equities analysts forecast that Cogent Biosciences will post -2.25 EPS for the current fiscal year.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.